top of page
Foot and beach

References

​1.British Association of Dermatologists’ guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014;171(5):937-958.


2.Thomas J et al., Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther. 2010 Oct; 35(5):497-519.


3.Elewski BE et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68(4):600-608.


4.JUBLIA® Prescribing Information.


5.Data on File. Confidential company data.

6. J Drugs Dermatol.2021;20(10)

JUBLIA®︎ is a prescription drug. The effectiveness and side effects of the medication may vary among individuals. Please consult your doctor or pharmacist for more information.

Disclaimer

All rights reserved. © 2020 Main Life Corp., Ltd.

The product information provided in this site is intended for residents of Hong Kong.

The health information is provided for reference only and is not intended to replace discussions with a healthcare provider.

All decisions regarding patient care must be made with healthcare provider.

JUBLIA® is a registered trademark of Kaken Pharmaceutical Co., Ltd.

  • YouTube
bottom of page